Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis

NCT03040765 is registered in ClinicalTrials.gov with Hamad Medical Corporation as lead sponsor.

NCT NCT03040765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03040765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis
Lead sponsor
Hamad Medical Corporation
Phase
Phase 3
Overall status
Terminated
Start date
May 14, 2018
Completion date
April 8, 2019
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis, thalassemia majors (beta-thalassemia major)